Gene Solutions Makes a Significant Move in Turkey's Oncology Landscape at the International Hereditary Cancers Congress

Gene Solutions' Strategic Launch in Türkiye

Gene Solutions, a leading biotechnology firm, has made a notable entrance into the Turkish market during the recently concluded 2nd International Hereditary Cancers Congress, which took place from February 5-8, 2026, in Antalya. This congress, organized by the Hereditary Cancer Association, gathered an impressive assembly of over 600 professionals in oncology and genetics, emphasizing ongoing advancements in hereditary cancer prevention and precision medicine.

Promoting Evidence-Based Oncology

As the landscape of hereditary cancer management progresses towards personalized detection and surveillance, the congress served as an essential platform to explore the practical integration of genomic medicine. In collaboration with ATC Genomics Sağlık Teknolojileri A.Ş., a well-respected player in molecular diagnostics with over three decades of experience, Gene Solutions presented significant real-world evidence derived from one of the largest Asian cohorts. The presentation focused on their AI-powered Multi-Cancer Early Detection (MCED) assay, highlighting its potential in improving patient outcomes.

The showcased ctDNA-powered oncology portfolio includes several cutting-edge solutions:
1. SPOT-MAS™ - AI-driven Multi-Cancer Early Detection.
2. K-4CARE™ - Comprehensive Genomic and Transcriptomic Profiling with ongoing minimal residual disease (MRD) monitoring.

These technologies aim to provide scalable and accessible precision oncology solutions for high-risk and hereditary patient populations, meeting the highest international standards for clinical performance.

Engaging the Oncology Community

Gene Solutions and ATC Genomics organized an Industry Satellite Symposium titled, "From Screening to Precision Care: The ctDNA Continuum in Oncology – Insights for High-Risk and Hereditary Populations." Co-chaired by eminent oncologists, the program focused on delivering actionable insights from early screening to treatment planning and long-term monitoring, particularly targeting hereditary and high-risk cohorts.

Dr. Le Son Tran, a principal investigator at Gene Solutions, highlighted the capabilities of the SPOT-MAS technology, emphasizing its integration of comprehensive blood-based analyses to detect multiple cancer types effectively. His presentation provided critical insights into the technology's accuracy and its significant implications for population health among high-risk groups. Follow-up discussions during the symposium further cemented the community's commitment to utilizing innovative solutions for early cancer detection and respective management.

Highlighting Real-World Evidence

Dr. Luu Hong Dang Nguyen of Gene Solutions presented an essential dataset derived from a cohort of 12,281 participants, showcasing remarkable metrics of sensitivity and specificity in cancer detection. This research not only advocates for the notion of "cancer interception"—the proactive identification and management of cancerous lesions—but it also underlines Gene Solutions’ focus on genetically predisposed and familial cancer cohorts.

In a statement reflecting the partnership’s potential, Dr. Özgüncem Bozkulak, General Manager of Gene Solutions' TR-EEMEA-CIS region, remarked, "Türkiye serves as a strategic gateway for precision oncology across Europe, Central Asia, and the Middle East, and we are excited to offer locally validated ctDNA solutions to clinicians dedicated to improving patient outcomes."

Burcu Torun, Managing Partner at ATC Genomics, echoed this sentiment, highlighting the collaboration as a pivotal step in enhancing the access and implementation of cutting-edge molecular diagnostics in Turkey.

Looking Ahead

The genetic testing landscape is rapidly evolving, and Gene Solutions aims to navigate this transformation by making advanced genomic solutions both accessible and affordable. With a goal to improve outcomes through early cancer detection and tailored treatment strategies, the company is committed to benefiting the Turkish oncology community and beyond.

Gene Solutions has already conducted over three million genetic tests globally since its inception, emphasizing its innovative approach and dedication to precision healthcare. Collaborating with ATC Genomics, the company is poised to contribute significantly to the ongoing developments in oncology.

To explore more about Gene Solutions and its offerings, please visit their official website at Gene Solutions.